HomepageGRF.P • BME
add
Grifols
Vorige slotkoers
€ 7,31
Dag-range
€ 7,16 - € 7,32
Jaar-range
€ 6,05 - € 9,73
Beurswaarde
5,79Â mld. EUR
Gem. volume
177,97K
Koers/winst
12,19
Dividendrendement
2,08%
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,98Â mld. | 0,32% |
Bedrijfskosten | 353,11Â mln. | 0,09% |
Netto inkomsten | 98,25Â mln. | 42,29% |
Netto winstmarge | 4,96 | 41,71% |
Winst per aandeel | — | — |
EBITDA | 422,88Â mln. | -14,62% |
Effectief belastingtarief | -13,21% | — |
Balans
Totale activa
Totale passiva
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 849,00Â mln. | -15,44% |
Totale activa | 19,71Â mld. | -7,91% |
Totale passiva | 12,11Â mld. | -5,39% |
Totaal aandelenvermogen | 7,60 mld. | — |
Uitstaande aandelen | 680,58 mln. | — |
Koers-boekwaardeverhouding | 0,94 | — |
Rendement op activa | 4,39% | — |
Rendement op kapitaal | 5,04% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 98,25Â mln. | 42,29% |
Operationele kasstroom | 430,86Â mln. | -16,25% |
Kasstroom uit beleggingen | -151,32Â mln. | 15,45% |
Kasstroom uit financiering | -75,18Â mln. | -173,90% |
Nettomutatie in liquide middelen | 203,82Â mln. | -39,27% |
Vrije kasstroom | 349,39Â mln. | 243,02% |
Over
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Opgericht
18 nov 1940
Website
Werknemers
25.258